The Use of miRNA Panel as a Growth Plate Marker of Short‐Term Response to GH

• DOI: 10.1111/cen.15278
• Publication Date: 2025-05-21T05:44:26Z
• Authors: Caroline Rosa Pel...; Thayna Rosa Bispo; Itatiana Ferreira...; Leandra Steinmetz; Adriana Aparecida...; Angela Maria Spin...; Durval Damiani; Cristiane Kochi; Carlos Alberto Lo...
• Keywords: Human growth hormone

ABSTRACT Introduction Recombinant human growth hormone (GH) therapy shows variable responses in patients with deficiency (GHD), highlighting the need for reliable biomarkers to predict individual sensitivity. Objective This study investigated circulating microRNAs (miRNAs) involved plate regulation during GH prepubertal children GHD, aiming establish a miRNA panel correlating responsiveness. Patients and Methods Sixteen were treated daily recombinant (0.033 mg/kg) 6 months. Two participants excluded protocol noncompliance, one withdrew due spontaneous onset of puberty. Circulating levels six miRNAs (miR‐22‐3p, miR‐30c‐5p, miR‐140‐5p, miR‐340‐5p, miR‐494‐3p, miR‐16‐5p) measured via digital PCR at baseline 1, 3, months therapy. Clinical data (height, weight, velocity) collected simultaneously. Results All displayed characteristic response pattern: significant increases 1 months, transient decline 3 Despite these changes, no correlations identified between velocity, height SDS, or IGF‐1 levels. The included treatment‐naïve those prior following 30‐day wash‐out period. While group exhibited greater height‐SDS gains ( p = 0.008), differences expression observed groups, nor was there correlation increments. Conclusion this treatment‐responsive miRNAs, it did not correlate outcomes. Increasing sample size incorporating additional could enhance its clinical utility predicting treatment sensitivity GHD patients. Trial Registration NCT05946915.